Abstract: The invention provides antibodies that bind specifically to human indoleamine 2,3-dioxygenase 1 (IDO1), nucleic acids encoding the same, and methods of using the same. The antibodies are capable of binding to a sequence comprising SEQ ID NO: 1 and specifically bind to human IDO1 in formalin fixed paraffin embedded tissues. The antibodies are useful in a number of different analytical techniques, including immunohistochemistry (IHC) and immunocytochemistry (ICC).

Abstract: Provided herein are B7-H3 antibodies, fragments of such antibodies, and compositions comprising the same. The antibodies, antibody fragments and compositions are useful in a number of analytical methods, including immunohistochemical and immunocytochemical detection and analysis of B7-H3. Also provided herein are isolated peptides, compositions, and fusion proteins containing immunogenic determinants for said B7-H3 antibodies, animals immunized with the peptides and fusion proteins, isolated B cells obtained from the animals, and hybridomas made from the isolated B cells.

Abstract: Systems are provided for configuring applications in a distributed environment to enable more granular customization of application behavior. A centralized hierarchical configuration data store may be used to store configurations corresponding to a multi-level hierarchical model. The distributed environment may include a plurality of applications hosted by a plurality of application servers, where the application servers and/or applications are associated with an environment, an instance, and a category. The plurality of applications may load and apply configurations via a configuration control engine from the centralized hierarchical configuration data store based on the environment, instance, and category associated with the applications.

Abstract: The invention provides antibodies that bind specifically to human indoleamine 2,3-dioxygenase 1 (IDO1), and methods of using the same. The antibodies are capable of binding to a sequence comprising SEQ ID NO: 1 and specifically bind to human IDO1 in formalin fixed paraffin embedded tissues. The antibodies are useful in a number of different analytical techniques, including immunohistochemistry (IHC) and immunocytochemistry (ICC).

Abstract: The present application discloses anti-GPNMB antibodies and methods of using the same. The antibodies are selected to bind to an epitope located in a C-terminal fragment of the protein and are selected for specificity in immunohistochemical assays. The antibodies are useful in, for example, immunohistochemical methods of detecting GPNMB-positive cells in tumors.

Abstract: The invention provides antibodies immunoreactive with human OX40 and methods of using the same. The antibodies are reactive with a portion of the C-terminus of the human OX40 protein that includes amino acids 266-277. The antibodies are useful for detecting OX40 protein expression in human tissue samples, including by immunohistochemistry, immunofluorescence, or immunoblot.

Abstract: The invention provides anti-human pro-epiregulin and anti-human amphiregulin antibodies and methods of using the same. Anti-EREG antibodies raised against amino acids 148-169 and 156-169 of the human EREG protein, and anti-AREG antibodies raised against amino acids 238-252 of the human AREG protein are disclosed. Methods of using these antibodies to detect EREG and AREG and kits and other products for performing such methods are also disclosed.

Abstract: Provided herein are PD-L1 antibodies and methods for using the same for detecting human PD-L1 protein in biological samples. The PD-L1 antibodies and methods may be useful for diagnosing a medical condition associated with elevated PD-L1 levels (e.g., cancer) in subjects in need thereof and in evaluating the efficacy of a particular therapeutic regime in a subject diagnosed as having a PD-L1-related medical condition, among other uses.

Abstract: Embodiments of the invention are directed to systems, methods and computer program products for creating and managing a virtual operating environment on a physical machine connected to a distributed network, the virtual operating environment is virtualized by the physical machine. The invention may categorize the virtual operating environment using a tiered data structure, where each tier of the tiered data structure defines an attribute for categorizing the virtual operating environment. The invention generates a graphical representation of the tiered data structure for display via a user computing device that enables a user to communicate requests for causing the virtual operating environment to perform a function and communicates commands to the physical machine based on receiving such requests. The invention may additionally update the graphical representation after the virtual operating environment has executed the function.

Abstract: Provided herein are PD-L1 antibodies and methods for using the same for diagnosing a medical condition associated with elevated PD-L1 levels (e.g., cancer) in subjects in need thereof and antigen binding fragments thereof. The PD-L1 antibodies and antigen binding fragments are also useful in evaluating the efficacy of a particular therapeutic regime in a subject diagnosed as having a PD-L1-related medical condition.

Abstract: Antibodies, compositions, systems, and methods for detecting C4.4a, for example immunohistochemistry methods for detecting C4.4a using a C4.4a antibody. The antibody may be obtained by immunizing a host with a C4.4a protein such as a peptide downstream of the signal peptide. The antibodies may be adapted to detect the uPAR-like domain 1 and uPAR-like domain 2. Also featured are methods for diagnosing C4.4a-associated tumors using C4.4a antibodies disclosed herein.

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Abstract: Systems are provided for configuring applications in a distributed environment to enable more granular customization of application behavior. A centralized hierarchical configuration data store may be used to store configurations corresponding to a multi-level hierarchical model. The distributed environment may include a plurality of applications hosted by a plurality of application servers, where the application servers and/or applications are associated with an environment, an instance, and a category. The plurality of applications may load and apply configurations via a configuration control engine from the centralized hierarchical configuration data store based on the environment, instance, and category associated with the applications.

Abstract: The invention provides antibodies that bind specifically to human indoleamine 2,3-dioxygenase 1 (IDO1), and methods of using the same. The antibodies are capable of binding to a sequence comprising SEQ ID NO: 1 and specifically bind to human IDO1 in formalin fixed paraffin embedded tissues. The antibodies are useful in a number of different analytical techniques, including immunohistochemistry (IHC) and immunocytochemistry (ICC).

Abstract: Provided herein are B7-H3 antibodies, fragments of such antibodies, and compositions comprising the same. The antibodies, antibody fragments and compositions are useful in a number of analytical methods, including immunohistochemical and immunocytochemical detection and analysis of B7-H3. Also provided herein are isolated peptides, compositions, and fusion proteins containing immunogenic determinants for said B7-H3 antibodies, animals immunized with the peptides and fusion proteins, isolated B cells obtained from the animals, and hybridomas made from the isolated B cells.

Abstract: Embodiments of the invention are directed to systems, methods and computer program products for creating and managing a virtual operating environment on a physical machine connected to a distributed network, the virtual operating environment is virtualized by the physical machine. The invention may categorize the virtual operating environment using a tiered data structure, where each tier of the tiered data structure defines an attribute for categorizing the virtual operating environment. The invention generates a graphical representation of the tiered data structure for display via a user computing device that enables a user to communicate requests for causing the virtual operating environment to perform a function and communicates commands to the physical machine based on receiving such requests. The invention may additionally update the graphical representation after the virtual operating environment has executed the function.

Abstract: Embodiments of the invention are directed to systems, methods and computer program products for creating and managing a virtual operating environment on a physical machine connected to a distributed network, the virtual operating environment is virtualized by the physical machine. The invention may categorize the virtual operating environment using a tiered data structure, where each tier of the tiered data structure defines an attribute for categorizing the virtual operating environment. The invention generates a graphical representation of the tiered data structure for display via a user computing device that enables a user to communicate requests for causing the virtual operating environment to perform a function and communicates commands to the physical machine based on receiving such requests. The invention may additionally update the graphical representation after the virtual operating environment has executed the function.

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Abstract: Provided herein are novel PD-L1 antibodies and methods for using the same for diagnosing a medical condition associated with elevated PD-L1 levels (e.g., cancer) in subjects in need thereof and antigen binding fragments thereof. The PD-L1 antibodies and antigen binding fragments are also useful in evaluating the efficacy of a particular therapeutic regime in a subject diagnosed as having a PD-L1-related medical condition.

Abstract: A tissue culture system for production of infectious hepatitis C virus is described. In particular, the invention provides recombinant monocistronic and bicistronic genomic constructs for production of virus, including constructs for production of wild-type HCV type 2a strain JFH1 and constructs for production of chimeric viruses comprising HCV proteins from strain JFH1 and a second HCV isolate. Constructs of the invention also include a reporter gene to facilitate measurement of RNA replication and viral infectivity in cultures. The cell culture system may also include various factors that improve viral replication or infectivity. In addition, a neutralization assay using HCV grown in cell culture is described.